188 related articles for article (PubMed ID: 36813928)
1. Bevacizumab in real-life patients with recurrent glioblastoma: benefit or futility?
Smolenschi C; Rassy E; Pallud J; Dezamis E; Copaciu R; Parker F; Garcia G; Lezghed N; Colomba E; Khettab M; Ammari S; Fekhi M; Martanovschi L; Benadhou L; Knafo S; Guyon D; Cheaib B; Dhermain F; Dumont SN
J Neurol; 2023 May; 270(5):2702-2714. PubMed ID: 36813928
[TBL] [Abstract][Full Text] [Related]
2. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
4. Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab.
Manneh Kopp RA; Sepúlveda-Sánchez JM; Ruano Y; Toldos O; Pérez Núñez A; Cantero D; Hilario A; Ramos A; de Velasco G; Sánchez-Gómez P; Hernández-Laín A
Clin Transl Oncol; 2019 Oct; 21(10):1413-1423. PubMed ID: 30877636
[TBL] [Abstract][Full Text] [Related]
5. Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen.
Tabouret E; Barrie M; Thiebaut A; Matta M; Boucard C; Autran D; Loundou A; Chinot O
J Neurooncol; 2013 Sep; 114(2):191-8. PubMed ID: 23756726
[TBL] [Abstract][Full Text] [Related]
6. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
Park JE; Kim HS; Park SY; Jung SC; Kim JH; Heo HY
Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775
[TBL] [Abstract][Full Text] [Related]
7. Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab.
Grossmann P; Narayan V; Chang K; Rahman R; Abrey L; Reardon DA; Schwartz LH; Wen PY; Alexander BM; Huang R; Aerts HJWL
Neuro Oncol; 2017 Nov; 19(12):1688-1697. PubMed ID: 28499022
[TBL] [Abstract][Full Text] [Related]
8. Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study.
Morisse MC; Etienne-Selloum N; Bello-Roufai D; Blonski M; Taillandier L; Lorgis V; Noël G; Ahle G; Durán-Peña A; Boone M; Chauffert B
J Neurooncol; 2019 Sep; 144(2):419-426. PubMed ID: 31325146
[TBL] [Abstract][Full Text] [Related]
9. ADC quantification to classify patients candidate to receive bevacizumab treatment for recurrent glioblastoma.
Asenjo García B; Navarro Guirado F; Nagib Raya F; Vidal Denis M; Bravo Rodríguez F; Galán Montenegro P
Acta Radiol; 2020 Mar; 61(3):404-413. PubMed ID: 31357873
[No Abstract] [Full Text] [Related]
10. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
Reardon DA; Brandes AA; Omuro A; Mulholland P; Lim M; Wick A; Baehring J; Ahluwalia MS; Roth P; Bähr O; Phuphanich S; Sepulveda JM; De Souza P; Sahebjam S; Carleton M; Tatsuoka K; Taitt C; Zwirtes R; Sampson J; Weller M
JAMA Oncol; 2020 Jul; 6(7):1003-1010. PubMed ID: 32437507
[TBL] [Abstract][Full Text] [Related]
11. Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors.
Johansen MD; Urup T; Holst CB; Christensen IJ; Grunnet K; Lassen U; Friis S; Poulsen HS
Cancer Invest; 2018; 36(9-10):512-519. PubMed ID: 30727779
[TBL] [Abstract][Full Text] [Related]
12. Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.
Galla N; Chiang G; Chakraborty S; Singh R; John Tsiouris A; Boockvar J; Kovanlikaya I
Neuroradiology; 2017 May; 59(5):499-505. PubMed ID: 28343250
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of recurrent glioblastoma with single-agent bevacizumab].
Sinkó D; Nemeskéri C
Orv Hetil; 2016 Mar; 157(13):500-3. PubMed ID: 26996897
[TBL] [Abstract][Full Text] [Related]
14. Salvage therapy with single agent bevacizumab for recurrent glioblastoma.
Chamberlain MC; Johnston SK
J Neurooncol; 2010 Jan; 96(2):259-69. PubMed ID: 19593660
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab and Bevacizumab in Glioblastoma.
Carter T; Shaw H; Cohn-Brown D; Chester K; Mulholland P
Clin Oncol (R Coll Radiol); 2016 Oct; 28(10):622-626. PubMed ID: 27169593
[TBL] [Abstract][Full Text] [Related]
16. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
Hilario A; Sepulveda JM; Hernandez-Lain A; Salvador E; Koren L; Manneh R; Ruano Y; Perez-Nuñez A; Lagares A; Ramos A
Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
[TBL] [Abstract][Full Text] [Related]
17. Clinical Impact of Bevacizumab in Patients with Relapsed Glioblastoma: Focus on a Real-Life Monocentric SurVey (SV1 Study).
Rivoirard R; Chargari C; Guy JB; Nuti C; Peoc'h M; Forest F; Falk AT; Garin C; Adjabi A; Hoarau D; Fotso MJ; Langrand Escure J; Moriceau G; Fournel P; Boutet C; Magné N
Chemotherapy; 2016; 61(5):269-74. PubMed ID: 27057742
[TBL] [Abstract][Full Text] [Related]
18. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.
Lassen U; Chinot OL; McBain C; Mau-Sørensen M; Larsen VA; Barrie M; Roth P; Krieter O; Wang K; Habben K; Tessier J; Lahr A; Weller M
Neuro Oncol; 2015 Jul; 17(7):1007-15. PubMed ID: 25665807
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab for recurrent glioblastoma: a systematic review and meta-analysis.
Zhang T; Xin Q; Kang JM
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(21):6480-6491. PubMed ID: 34787852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
